MedPath

Prognosis Of Patients With Aggressive B-Cell Lymphoma, Treated With Rituximab+Anthracycline Regimen

Completed
Conditions
B-Cell Lymphomas
Registration Number
NCT01478269
Lead Sponsor
Fondazione Italiana Linfomi - ETS
Brief Summary

This study is a retrospective analysis of an homogeneous population of patients with aggressive B-cell lymphoma and treated upfront with R-CHOP or R-CHOP like regimens to reassess the prognostic factors and hopefully to identify more accurate prognostic subgroups with a clinical and therapeutical relevance.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
1927
Inclusion Criteria
  1. Histologically confirmed newly diagnosed aggressive B-cell lymphoma according to the current World Health Organisation Classification, from 2001 to 2007.
  2. Any stage of disease.
  3. Treatment with R-CHOP or R-CHOP like regimens (+/- transplant).
  4. Age at least 18 years.
  5. Availability of tissue biopsy at diagnosis for a possible centralized revision.
  6. Availability of data on clinical involvement, laboratory, treatment and follow up.
Exclusion Criteria
  • None

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (39)

Hemocentro-Unicamp

🇧🇷

Campinas, Brazil

Centro Medico

🇧🇷

Santa Isabel, Brazil

Centro Paulista de Oncologia

🇧🇷

Sao Paolo, Brazil

Santa Casa Medical School

🇧🇷

Sao Paolo, Brazil

A.O.SS. Biagio, Antonio e Cesare Arrigo

🇮🇹

Alessandria, Italy

Centro di riferimento Oncologico Oncologia Medica A

🇮🇹

Aviano (Pordenone), Italy

USC Ematologia e Trapianto di Midollo Osseo Ospedali Riuniti di Bergamo

🇮🇹

Bergamo, Italy

Presidio Ospedaliero A.Perrino - Divisione di Ematologia

🇮🇹

Brindisi, Italy

U.O. di Oncologia Ospedale di Circolo di Busto Arsizio

🇮🇹

Busto Arsizio, Italy

Ospedale Civile

🇮🇹

Camposanpiero (PD), Italy

Scroll for more (29 remaining)
Hemocentro-Unicamp
🇧🇷Campinas, Brazil

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.